Search Result

Results for "

higher affinity

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (7) Adenosine Receptor (1) Adhesion G Protein-coupled Receptors (AGPCRs) (1) Adrenergic Receptor (10) Antibiotic (3) Apoptosis (7) Autophagy (4) Bacterial (3) Bcl-2 Family (1) Biochemical Assay Reagents (3) Calcium Channel (1) CaMK (1) CDK (1) Cholinesterase (ChE) (2) CXCR (1) Cytochrome P450 (4) Dopamine Receptor (5) Drug Metabolite (8) Elastase (1) Endogenous Metabolite (5) ERK (1) Estrogen Receptor/ERR (14) GABA Receptor (1) Histamine Receptor (5) HIV Protease (1) HSP (3) Influenza Virus (1) Isotope-Labeled Compounds (6) Leukotriene Receptor (2) Melanocortin Receptor (2) mGluR (1) Mitophagy (3) Monoamine Oxidase (1) nAChR (3) Neurokinin Receptor (2) Neuropeptide Y Receptor (2) Parasite (4) Phosphatase (3) Potassium Channel (3) PPAR (1) PROTACs (1) Proton Pump (1) RAR/RXR (2) Reactive Oxygen Species (ROS) (3) Reference Standards (10) Serotonin Transporter (6) Thyroid Hormone Receptor (1) Transmembrane Glycoprotein (1) Trk Receptor (1) TRP Channel (1) Xanthine Oxidase (1) YAP (2)
By Research Areas:	Cancer (33) Cardiovascular Disease (6) Endocrinology (10) Infection (4) Inflammation/Immunology (15) Metabolic Disease (8) Neurological Disease (38)
Click Chemistry:	Alkynes (1)

100

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: MARK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10684

Pridopidine ACR16; ASP2314; FR310826	Dopamine Receptor	Neurological Disease
Pridopidine, a dopamine (DA) stabilizer, acts as a low affinity dopamine D2 receptor (D2R) antagonist. Pridopidine exerts high affinity towards sigma 1 receptor (S1R) with K_i between 70 and 80 nM, which is ~100× higher than its affinity toward D2R.

HY-P3205

Lysyl endopeptidase, Achromobacter sp 1 Publications Verification Lys-C	Biochemical Assay Reagents	Others
Lysyl endopeptidase, Achromobacter sp (Lys-C) catalyzes carboxyl oxygen exchange reaction. Lysyl endopeptidase has higher substrate binding affinities and higher catalytic rates at the acidic pHs than at the alkaline pHs .

HY-119518

BMS641 BMS-209641	RAR/RXR	Cancer
BMS641 (BMS-209641) is a selective RARβ agonist. BMS641 has a higher affinity for RARβ (K_d, 2.5 nM) that is 100 times higher than that for RARα (K_d, 225 nM) or RARγ (K_d, 223 nM) .

HY-P1135

M1145	Neuropeptide Y Receptor	Neurological Disease
M1145, a chimeric peptide, is a selective galanin receptor type 2 (GAL2) agonist, with a K_i of 6.55 nM. M1145 shows more than 90-fold higher affinity for GAL2 over GAL1 (K_i=587 nM) and a 76-fold higher affinity over GalR3 (K_i=497 nM). M1145 has an additive effect on the signal transduction of galanin .

HY-161168

Cyclin K degrader 1	CDK	Cancer
Cyclin K degrader 1 (compound 40) is an AT7519 (HY-50940) based Cyclin K degrader with DC₅₀ of 21 nM. Cyclin K degrader 1 has an affinity for cyclin K that is ~500-fold higher than its affinity for CDK12 .

HY-176305S

Neurofilament, U-15N	Isotope-Labeled Compounds	Neurological Disease
Neurofilament, U- ¹⁵N is the ¹⁵N-labeled Neurofilament.

HY-121166

Levobetaxolol (S)-Betaxolol	Adrenergic Receptor	Others
Levobetaxolol is a potent and high affinity β-adrenergic antagonist with IC₅₀ values of 33.2, 2970, 709 nM for guinea pig atrial β1, tracheal β2 and rat colonic β3 receptors, respectively. Levobetaxolol reduces IOP (intraocular pressure). Levobetaxolol exhibits a micromolar affinity for L-type Ca21-channels. Levobetaxolol decreases the effects of ischaemia/reperfusion injury in rats. Levobetaxolol has the potential for the research of glaucoma .

HY-101686

LM-1484	Leukotriene Receptor	Inflammation/Immunology
LM-1484 is an antagonist of CysLT1 receptor and displays a higher affinity for ³H-LTC4 sites.

HY-111210

Pridopidine hydrochloride ACR16 hydrochloride; ASP2314 hydrochloride; FR310826 hydrochloride	Dopamine Receptor	Neurological Disease
Pridopidine (ACR16) hydrochloride, a dopamine (DA) stabilizer, acts as a low affinity dopamine D2 receptor (D2R) antagonist. Pridopidine exerts high affinity towards sigma 1 receptor (S1R) with K_i between 70 and 80 nM, which is ~100-fold higher than its affinity toward D2R.

HY-P1135A

M1145 TFA	Neuropeptide Y Receptor	Neurological Disease
M1145 TFA, a chimeric peptide, is a selective galanin receptor type 2 (GAL2) agonist, with a K_i of 6.55 nM. M1145 TFA shows more than 90-fold higher affinity for GAL2 over GAL1 (K_i=587 nM) and a 76-fold higher affinity over GalR3 (K_i=497 nM). M1145 TFA has an additive effect on the signal transduction of galanin .

HY-10684R

Pridopidine (Standard)	Dopamine Receptor	Neurological Disease
Pridopidine (Standard) is the analytical standard of Pridopidine. This product is intended for research and analytical applications. Pridopidine, a dopamine (DA) stabilizer, acts as a low affinity dopamine D2 receptor (D2R) antagonist. Pridopidine exerts high affinity towards sigma 1 receptor (S1R) with Ki between 70 and 80 nM, which is ~100× higher than its affinity toward D2R.

HY-100202

TPEN 15+ Cited Publications TPEDA	Reactive Oxygen Species (ROS) Apoptosis Autophagy	Cancer
TPEN (TPEDA) is a specific cell-permeable heavy metal chelator. TPEN has a higher affinity for Zn ²⁺, but a lower affinity for Mg ²⁺ and Ca ²⁺. TPEN induces DNA damage and increases intracellular ROS production. TPEN also inhibits cell proliferation and induces apoptosis .

HY-122294

Rociverine	Endogenous Metabolite	Neurological Disease
Rociverine is an anticholinergic compound with smooth muscle relaxant activity. Rociverine showed different binding modes in five cloned muscarinic receptors. The cis stereoisomer of Rociverine showed a higher affinity change compared to the trans stereoisomer. The (1R,2R) configuration of Rociverine showed significantly higher affinity, even up to 240 times. The (1S,2S) configuration of Rociverine is very important for binding selectivity .

HY-156394

Laxiflorin B-4	ERK	Cancer
Laxiflorin B-4 is modificative compound of Laxiflorin B (HY-156393), exhibited higher affinity for ERK1/2 and stronger tumor suppression .

HY-18719B

Endoxifen hydrochloride 1 Publications Verification	Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite	Cancer
Endoxifen hydrochloride is a key active metabolite of Tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen hydrochloride has the potential for breast cancer study .

HY-18719E

Endoxifen 1 Publications Verification	Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite	Cancer
Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study .

HY-16381C

(2R)-Pasireotide (diaspartate) (2R)-SOM230 (diaspartate)	Endogenous Metabolite	Others
(2R)-Pasireotide ((2R)-SOM230) diaspartate exhibits a 40-fold higher affinity for somatostatin receptor 5 than other somatostatin analogs.

HY-105346

WIN 51708	Neurokinin Receptor	Neurological Disease
WIN 51708 is a nonpeptide antagonist of neurokinin (NK)-1 receptor. WIN 51708 has a higher affinity for the rat NK-1 receptor compared to the human NK-1 receptor .

HY-124414

4'-Hydroxytamoxifen	Estrogen Receptor/ERR Drug Metabolite	Cancer
4'-Hydroxytamoxifen is a metabolite of Tamoxifen. 4'-Hydroxytamoxifen shows higher affinity for the ER than Tamoxifen. 4'-Hydroxytamoxifen induces a non-apoptotic cytotoxic effect in human endometrial adenocarcinoma cells .

HY-123567

LY86057	5-HT Receptor	Neurological Disease
LY86057 is an ergoline derivative without N1 substituents. It has higher affinity for porcine, squirrel monkey and human 5-HT2 receptors than rats and is an antagonist of 5-HT2 receptors. When studying the differences in recognition of a series of ergolines between species, LY86057 was found to be more selective for 5-HT2 receptors. Compared with LY53857, LY108742 resulted in a higher affinity for rat 5-HT2 receptors even when the N1 substituent was only methyl.

HY-15553B

Mibefradil dihydrochloride hydrate Ro 40-5967 dihydrochloride hydrate	Calcium Channel	Cardiovascular Disease Cancer
Mibefradil dihydrochloride hydrate (Ro 40-5967 dihydrochloride hydrate) is a effectively long-acting calcium channel antagonist, used as an antihypertensive agent. Mibefradil dihydrochloride hydrate acts via a higher affinity block for low-voltage-activated (T) than for high-voltage-activated (L) calcium channels .

HY-18719ES

Endoxifen-d5	Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite	Cancer
Endoxifen-d₅ is the deuterium labeled Endoxifen. Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study .

HY-124414A

4'-Hydroxytamoxifen TFA	Estrogen Receptor/ERR Drug Metabolite	Cancer
4'-Hydroxytamoxifen TFA is a salt form of a metabolite of Tamoxifen. 4'-Hydroxytamoxifen TFA has a higher affinity for ER than Tamoxifen. 4'-Hydroxytamoxifen TFA induces non-apoptotic cytotoxicity in human endometrial adenocarcinoma cells .

HY-147908

Adenosine receptor inhibitor 2	Xanthine Oxidase Adenosine Receptor	Inflammation/Immunology
Adenosine receptor inhibitor 2 (compound 14b) is a potent AR (adenosine receptor) inhibitor. Adenosine receptor inhibitor 2 shows dual affinity toward A₁/A_2A ARs with higher affinity for the A₁- than the A_2AAR. Adenosine receptor inhibitor 2 has K_i values of 52.2 nM for the A₁AR and 167 nM for the A_2AAR .

HY-100943

Cinanserin hydrochloride 1 Publications Verification SQ 10643	5-HT Receptor Influenza Virus	Infection Inflammation/Immunology
Cinanserin hydrochloride (SQ 10643) is a potent, selective and highly affinity 5-HT₂ receptor antagonist with a K_i of 41 nM. Cinanserin hydrochloride has a much higher binding affinity for the 5-HT₂ than for the 5-HT₁ receptor (K_i of 3500 nM). Cinanserin is also an inhibitor of 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro .

HY-18719BR

Endoxifen hydrochloride (Standard)	Cytochrome P450 Reference Standards Estrogen Receptor/ERR Drug Metabolite Parasite	Cancer
Endoxifen (hydrochloride) (Standard) is the analytical standard of Endoxifen (hydrochloride). This product is intended for research and analytical applications. Endoxifen hydrochloride is a key active metabolite of Tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen hydrochloride has the potential for breast cancer study[1][2].

HY-111142

COR 32-24	Others	Others
COR 32-24 is a compound that enters the brain through the purine transport system and has the activity of being transported by this system. The brain uptake index of COR 32-24 in rats decreases with the increase of the concentration of unlabeled compound, and its affinity for purine transporters is higher than that for adenine.

HY-100689

Propyl pyrazole triol 10+ Cited Publications PPT	Estrogen Receptor/ERR	Cancer
Propyl pyrazole triol (PPT) is a selective estrogen receptor alpha (ERα) agonist. The relative binding affinity of Propyl pyrazole triol for ERα (ERα: 49%) around 410 times higher compared with estrogen receptor beta (ERβ: 0.12%) .

HY-103138

(Rac)-WAY-161503 hydrochloride	5-HT Receptor	Neurological Disease Metabolic Disease
(Rac)-WAY-161503 hydrochloride is a potent, selective, high affinity 5-HT_2C receptor agonist with a K_i of 4 nM and an EC₅₀ of 12 nM. (Rac)-WAY-161503 hydrochloride displays higher affinity for 5-HT_2C than 5-HT_2A and 5-HT_2B receptors. (Rac)-WAY-161503 hydrochloride has anti-obesity and antidepressant effects .

HY-103138A

(Rac)-WAY-161503	5-HT Receptor	Neurological Disease Metabolic Disease
(Rac)-WAY-161503 is a potent, selective, highly affinity 5-HT_2C receptor agonist with a K_i of 4 nM and an EC₅₀ of 12 nM. (Rac)-WAY-161503 displays higher affinity for 5-HT_2C than 5-HT_2A and 5-HT_2B receptors. (Rac)-WAY-161503 has anti-obesity and antidepressant effects .

HY-129296

YM-44781 free acid	Endogenous Metabolite	Neurological Disease
YM-44781 free acid is a non-peptide neuropeptide receptor antagonist with efficient NK(2) and NK(1) receptor antagonist activity. YM-44781 exhibits significant binding affinity on the NK(2) receptor (pK_i = 9.94) and also on the NK(1) receptor Higher binding affinity (pK_i = 9.09). In addition, YM-44781 also showed significant inhibitory effects on bladder contraction induced by selective NK(1) receptor agonists .

HY-103451

(R,R)-THC	Estrogen Receptor/ERR	Metabolic Disease
(R,R)-THC is an ERα agonist and an ERβ antagonist, with K_is of 9.0 nM and 3.6 nM for ERα and ERβ, respectively. (R,R)-THC has higher relative binding affinity for ERβ than ERα with the values of 25 and 3.6 .

HY-116910

CPP-115	GABA Receptor	Neurological Disease
CPP-115 is a GABA transaminase inactivator with higher affinity and lower retinal toxicity than Vigabatrin (HY-15399). CPP-115 increases brain GABA levels by inhibiting GABA transaminase catabolism. CPP-115 can be used in the study of drug addiction and infantile spasms .

HY-P2244A

YAP-TEAD-IN-1 TFA 2 Publications Verification	YAP	Cancer
YAP-TEAD-IN-1 TFA is a potent and competitive peptide inhibitor of YAP-TEAD interaction (IC₅₀=25 nM). YAP-TEAD-IN-1 TFA is a 17mer peptide and shows a higher the binding affinity to TEAD1 (K_d=15 nM) than YAP (50-171) (K_d= 40 nM) .

HY-W420344

Dehydroindapamide	Potassium Channel	Others
Dehydroindapamide is the indole form of Indapamide (HY-B0259). Dehydroindapamide standard can be used to quantitatively measure the Indapamide turnover rate by CYP3A4, which was approximately 10-fold higher than that of Indoline (HY-Y0788), and slightly enhanced affinity for CYP3A4 .

HY-10473

Eprotirome KB2115	Thyroid Hormone Receptor	Metabolic Disease Endocrinology
Eprotirome (KB2115) is a liver-selective thyroid hormone receptor (TR) agonist. KB2115 has modestly higher affinity for TRβ than for TRα. Eprotirome reduces low-density lipoprotein (LDL) cholesterol concentrations. Eprotirome can be used for dyslipidemias and obesity research .

HY-P2244

YAP-TEAD-IN-1 2 Publications Verification	YAP	Cancer
YAP-TEAD-IN-1 is a potent and competitive inhibitor of?YAP–TEAD interaction (IC₅₀=25 nM). YAP-TEAD-IN-1 is a 17mer peptide and shows a higher the binding affinity to TEAD1 (K_d=15 nM) than YAP (50-171) (K_d=40 nM) .

HY-157287

(S)-Phe-A110/B319	Others	Inflammation/Immunology
(S)-Phe-A110/B319 is a selective binde that has 20-fold higher affinity towards the H1047R mutant of p110α in the p110α/p85α PI3K complex .

HY-W010841

Levocetirizine dihydrochloride 2 Publications Verification (R)-Cetirizine dihydrochloride	Histamine Receptor	Inflammation/Immunology Endocrinology Cancer
Levocetirizine dihydrochloride ((R)-Cetirizine dihydrochloride) is a third-generation peripheral H1-receptor antagonist. Levocetirizine dihydrochloride is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine dihydrochloride has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria .

HY-B0814

Levocetirizine 2 Publications Verification (R)-Cetirizine	Histamine Receptor	Inflammation/Immunology Endocrinology Cancer
Levocetirizine ((R)-Cetirizine) is a third-generation peripheral H1-receptor antagonist. Levocetirizine is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria .

HY-124414R

4'-Hydroxytamoxifen (Standard)	Reference Standards Estrogen Receptor/ERR Drug Metabolite	Cancer
4'-Hydroxytamoxifen (Standard) is the analytical standard of 4'-Hydroxytamoxifen. This product is intended for research and analytical applications. 4'-Hydroxytamoxifen is a metabolite of Tamoxifen. 4'-Hydroxytamoxifen shows higher affinity for the ER than Tamoxifen. 4'-Hydroxytamoxifen induces a non-apoptotic cytotoxic effect in human endometrial adenocarcinoma cells .

HY-P2468

BAD (103-127) (human) BADBH3 103-127 (human); BADBH3 (human)	Bcl-2 Family	Cancer
BAD (103-127) (human), the 25-mer Bad peptide, is derived from the BH3 domain of BAD, can antagonize the function of Bcl-xL. BAD (103-127) (human) is reported to have almost 800-fold higher affinity for Bcl-XL than the 16-mer peptide .

HY-14258

Escitalopram 5+ Cited Publications (S)-Citalopram; (S)-(+)-Citalopram	Serotonin Transporter	Neurological Disease
Escitalopram ((S)-Citalopram), the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a K_i of 0.89 nM. Escitalopram has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram is an antidepressant for the research of major depression .

HY-U00165

Midaglizole hydrochloride (±)-DG5128; DG5128	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Midaglizole hydrochloride (DG5128) is a preferential α2-adrenoceptor antagonist. Midaglizole hydrochloride (DG5128) exhibits 7.4 times higher affinity (pK_i=6.28) toward α2-adrenoceptor than α1-adrenoceptor.

HY-111241

SV 293	Dopamine Receptor	Neurological Disease
SV 293 is a selective antagonist with neutral antagonist activity. SV 293 binds to human D2 receptors with 100-fold higher affinity and has lower affinity for human D3 and D4 dopamine receptor subtypes. SV 293 was found to block the effects of the full agonist quinpirole in forskolin-dependent adenylate acylase inhibition assays and electrophysiological assays. SV 293 can be used as a useful pharmacological tool to study the role of dopamine D2-like receptor subtypes in dopamine pathways associated with neurological, neuropsychiatric and movement disorders .

HY-B1349

Mepiroxol	Biochemical Assay Reagents	Others
Mepiroxol can form various interactions with key residues of specific proteins. It establishes salt bridges with Arg-153 and Arg-74, and forms two hydrogen bonds with Asp-50 and Gly-96 through its terminal hydroxyl group, these interactions help enhance its binding affinity and lead to a higher docking score .

HY-111156

NW-1172 free base	Monoamine Oxidase	Neurological Disease
NW-1172 (free base) (compound 22b) is a 5-HT3 receptor antagonist with performance-enhancing activity in a delayed matching task in monkeys, with the (R) isomer producing more systematic improvements than the (S) isomer, a difference paralleled by the higher affinity of the (R) enantiomer for the 5-HT3 receptor.

HY-14258A

Escitalopram oxalate 5+ Cited Publications (S)-Citalopram oxalate; (S)-(+)-Citalopram oxalate	Serotonin Transporter	Neurological Disease Cancer
Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a K_i of 0.89 nM. Escitalopram oxalate has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .

HY-122140

ACG548B	Cholinesterase (ChE)	Neurological Disease
ACG548B (compound 24) is a potent inhibitor of acetyl- and butyrylcholinesterase (AChE and BChE) with IC₅₀s of 1.78 and 0.496 μM, respectively. ACG548B has higher AChE affinity and selectivity over BChE and ChoK (choline kinase). ACG548B can be uesd for the study of myasthenia gravis and neuromuscular blockade .

HY-103445

SSR69071	Elastase	Cardiovascular Disease
SSR69071 is a potent, orally active and selective inhibitor of neutrophil elastase. SSR69071 reduces myocardial infarct size following ischemia-reperfusion injury . SSR69071 displays a higher affinity for human elastase (K_i=0.0168 nM) than for rat (K_i=3 nM), mouse (K_i=1.8 nM), and rabbit (K_i= 58 nM) elastases .

Cat. No.	Product Name	Target	Research Area

HY-P2244A

YAP-TEAD-IN-1 TFA 2 Publications Verification	YAP	Cancer
YAP-TEAD-IN-1 TFA is a potent and competitive peptide inhibitor of YAP-TEAD interaction (IC₅₀=25 nM). YAP-TEAD-IN-1 TFA is a 17mer peptide and shows a higher the binding affinity to TEAD1 (K_d=15 nM) than YAP (50-171) (K_d= 40 nM) .

HY-P2244

YAP-TEAD-IN-1 2 Publications Verification	YAP	Cancer
YAP-TEAD-IN-1 is a potent and competitive inhibitor of?YAP–TEAD interaction (IC₅₀=25 nM). YAP-TEAD-IN-1 is a 17mer peptide and shows a higher the binding affinity to TEAD1 (K_d=15 nM) than YAP (50-171) (K_d=40 nM) .

HY-P2468

BAD (103-127) (human) BADBH3 103-127 (human); BADBH3 (human)	Bcl-2 Family	Cancer
BAD (103-127) (human), the 25-mer Bad peptide, is derived from the BH3 domain of BAD, can antagonize the function of Bcl-xL. BAD (103-127) (human) is reported to have almost 800-fold higher affinity for Bcl-XL than the 16-mer peptide .

HY-P1213

JKC363	Melanocortin Receptor	Neurological Disease
JKC363, a selective melanocortin MC4 receptor antagonist, has a 90-fold higher affinity at the MC4 receptor (IC₅₀=0.5 nM) than at the MC3 receptor (44.9 nM). JKC-363 blocks the stimulatory effect of α-MSH on TRH release. Anti-hyperalgesic effect .

HY-P5421

Caloxin 1B1	Proton Pump	Others
Caloxin 1B1 is a biological active peptide. (Caloxin 1b1 is obtained by screening for binding to extracellular domain 1 of PMCA4, which inhibited PMCA extracellularly, selectively, and had a higher affinity for PMCA4 than PMCA1. Because caloxin 1b1 had been selected to bind to an extracellular domain of PMCA, it could be added directly to cells and tissues to examine its effects on smooth muscle and endothelium.)

HY-P10365

VPM-p15	Adhesion G Protein-coupled Receptors (AGPCRs)	Others
Vmm-p15 is a peptide agonist optimized for the adhesion G protein-coupled receptor GPR64 (also known as ADGRG2 or HE6). The affinity of VPM-p15 with GPR64 is significantly higher than that of the original p15 peptide. The cAMP level induced by VMM-P15 increased significantly, activated GPR64, and triggered downstream Gs, Gq, and G12/13 signaling. VPM-p15 can be used to study the activation mechanism of adherent GPCR family members .

HY-P1135A

M1145 TFA	Neuropeptide Y Receptor	Neurological Disease
M1145 TFA, a chimeric peptide, is a selective galanin receptor type 2 (GAL2) agonist, with a K_i of 6.55 nM. M1145 TFA shows more than 90-fold higher affinity for GAL2 over GAL1 (K_i=587 nM) and a 76-fold higher affinity over GalR3 (K_i=497 nM). M1145 TFA has an additive effect on the signal transduction of galanin .

HY-P1213A

JKC363 TFA	Melanocortin Receptor	Neurological Disease
JKC363 TFA, a selective melanocortin MC4 receptor antagonist, has a 90-fold higher affinity at the MC4 receptor (IC₅₀=0.5 nM) than at the MC3 receptor (44.9 nM). JKC363 TFA blocks the stimulatory effect of α-MSH on TRH release. Anti-hyperalgesic effect .

HY-P11011

Peptide R54 Pep R54; CXCR4 antagonist peptide 19	CXCR	Cancer
Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic peptide targeting CXCR4 with significant anticancer activity. Peptide R54 inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and lung metastasis development, with better serum stability and higher CXCR4 affinity than the lead compound (IC₅₀=20 nM). Peptide R54 synergizes with anti-PD-1 therapy to exert anti-tumor activity in vivo, enhances granzyme activity, and reduces infiltration of Foxp3 cells. Peptide R54 can be used in the study of colon cancer, ovarian cancer, and melanoma .

Cat. No.	Product Name	Target	Research Area

HY-P99129

Anti-Mouse CD8a Antibody (53-6.7) 2 Publications Verification	Transmembrane Glycoprotein	Inflammation/Immunology
Anti-Mouse CD8a Antibody (53-6.7) is an anti-mouse CD8a IgG2a antibody inhibitor derived from host Rat. Anti-Mouse CD8a Antibody (53-6.7) binds to CD8αβ stabilizes a conformation with a higher affinity for interaction with MHC class I. Anti-Mouse CD8a Antibody (53-6.7) induces the phosphorylation and activation of TCR proximal signaling pathway components Lck and ZAP70 in polyclonal memory T cells. Anti-Mouse CD8a Antibody (53-6.7) depletes CD8+ T cells and neutralizes cytokine in mice .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-14258

Escitalopram 5+ Cited Publications (S)-Citalopram; (S)-(+)-Citalopram	Natural Products Source classification Endogenous metabolite	Serotonin Transporter
Escitalopram ((S)-Citalopram), the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a K_i of 0.89 nM. Escitalopram has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram is an antidepressant for the research of major depression .

HY-W013935

Bisphenol B	Structural Classification Classification of Application Fields Source classification Phenols Polyphenols Endogenous metabolite Disease Research Fields Endocrinology	Endogenous Metabolite Estrogen Receptor/ERR Reactive Oxygen Species (ROS)
Bisphenol B is a close structural analog of Bisphenol A (BPA) (HY-18260). Bisphenol B is a potent, orally active endocrine disruptor (ED). Bisphenol B binds to G protein-coupled estrogen receptor (GPER) (IC₅₀ = 3.3 μM) with higher affinity and agonistic activity than BPA. Bisphenol B promotes GPER mediated cell migration. Bisphenol B exerts estrogenic effects via GPER pathway at nanomolar concentration. Bisphenol B is used in the manufacture of polycarbonate resin with ED properties .

HY-14258R

Escitalopram (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Serotonin Transporter
Escitalopram (Standard) is the analytical standard of Escitalopram. This product is intended for research and analytical applications. Escitalopram ((S)-Citalopram), the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram has ～30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram is an antidepressant for the research of major depression .

HY-N6785

Okadaic acid	Structural Classification Animals Ketones, Aldehydes, Acids Marine natural products Source classification Other marine organisms	Phosphatase Apoptosis
Okadaic acid, a marine toxin, is an inhibitor of protein phosphatases (PP). Okadaic acid has a significantly higher affinity for PP2A (IC₅₀=0.1-0.3 nM), and inhibits PP1 (IC₅₀=15-50 nM), PP3 (IC₅₀=3.7-4 nM), PP4 (IC₅₀=0.1 nM), PP5 (IC₅₀=3.5 nM), but does not inhibit PP2C. Okadaic acid increases of phosphorylation of a number of proteins by inhibiting PP, and acts a tumor promoter. Okadaic acid induces tau phosphorylation .

HY-W013935R

Bisphenol B (Standard)	Structural Classification Source classification Phenols Polyphenols Endogenous metabolite	Reference Standards Endogenous Metabolite Estrogen Receptor/ERR Reactive Oxygen Species (ROS)
Bisphenol B (Standard) is the analytical standard of Bisphenol B. This product is intended for research and analytical applications. Bisphenol B is a close structural analog of Bisphenol A (BPA) (HY-18260). Bisphenol B is a potent, orally active endocrine disruptor (ED). Bisphenol B binds to G protein-coupled estrogen receptor (GPER) (IC₅₀ = 3.3 μM) with higher affinity and agonistic activity than BPA. Bisphenol B promotes GPER mediated cell migration. Bisphenol B exerts estrogenic effects via GPER pathway at nanomolar concentration. Bisphenol B is used in the manufacture of polycarbonate resin with ED properties .

Cat. No.	Product Name	Chemical Structure

HY-14258AS

Escitalopram-d6 oxalate

Escitalopram-d₆ (oxalate) is the deuterium labeled Escitalopram oxalate. Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a K_i of 0.89 nM. Escitalopram oxalate has ～30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .

HY-176305S

Neurofilament, U-15N
Neurofilament, U- ¹⁵N is the ¹⁵N-labeled Neurofilament.

HY-18719ES

Endoxifen-d5
Endoxifen-d₅ is the deuterium labeled Endoxifen. Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study .

HY-B0814S

Levocetirizine-d4 dihydrochloride

Levocetirizine-d₄ (dihydrochloride) is the deuterium labeled Levocetirizine. Levocetirizine ((R)-Cetirizine) is a third-generation peripheral H1-receptor antagonist. Levocetirizine is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria[1].

HY-144470S

Dehydroindapamide-d3
Dehydroindapamide-d₃ is the deuterium labeled Dehydroindapamide (HY-W420344). Dehydroindapamide is the indole form of Indapamide (HY-B0259). Dehydroindapamide standard can be used to quantitatively measure the Indapamide turnover rate by CYP3A4, which was approximately 10-fold higher than that of Indoline (HY-Y0788), and slightly enhanced affinity for CYP3A4 .

HY-14258AS1

Escitalopram-d4 oxalate

Escitalopram-d₄ (oxalate) is deuterium labeled Escitalopram (oxalate). Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a K_i of 0.89 nM. Escitalopram oxalate has ～30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression .

HY-B0814S1

Levocetirizine-d4

Levocetirizine-d₄ ((R)-Cetirizine-d₄) is the deuterium-labeled Levocetirizine (HY-B0814) . Levocetirizine ((R)-Cetirizine) is a third-generation peripheral H1-receptor antagonist. Levocetirizine is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria .

HY-10211S

Tanespimycin-d5

Tanespimycin-d₅ (17-AAG-d₅; NSC 330507-d₅; CP 127374-d₅) is the deuterium labeled Tanespimycin (HY-10211). Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC₅₀ of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90 . Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression .

Cat. No.	Product Name		Classification